Stocktoria
Anixa Biosciences Inc ANIX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1983-10-07
Anixa Biosciences Inc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $210,000 | $210,000 | — | $512,000 | — | $250,000 | $1.1M | $362,500 | $300,000 |
| R&D expense | $5.1M | $6.4M | $4.8M | $6.7M | $6.2M | $4.4M | $5.5M | $6.8M | $1.6M | $1.6M |
| SG&A expense | — | — | — | — | — | — | $5.7M | $6.9M | $4.4M | $2.7M |
| Operating income | -$11.7M | -$13.8M | -$11.0M | -$13.9M | -$13.1M | -$10.0M | -$11.9M | -$14.3M | -$6.1M | -$4.5M |
| Interest expense | — | — | — | — | — | — | — | — | $500,455 | $519,946 |
| Net income | -$10.9M | -$12.6M | -$9.8M | -$13.6M | -$13.0M | -$10.0M | -$11.6M | -$14.0M | -$5.0M | -$5.0M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.32 | $0.45 | — | — | — | — | — | — |
| Operating cash flow | -$7.2M | -$7.3M | -$6.2M | -$6.5M | -$4.9M | -$6.2M | -$4.7M | -$4.3M | -$3.8M | -$3.4M |
| Free cash flow | — | — | — | — | — | -$6.2M | -$4.9M | -$4.3M | -$3.8M | -$3.5M |
| Cash & equivalents | $1.2M | $1.3M | $915,000 | $12.4M | $29.1M | $6.4M | $3.5M | $3.1M | $3.3M | $2.5M |
| Total assets | $16.1M | $21.6M | $25.5M | $30.4M | $36.3M | $9.5M | $6.3M | $6.4M | $8.8M | $5.6M |
| Total liabilities | $2.1M | $2.7M | $2.2M | $2.2M | $1.5M | $1.2M | $1.5M | — | $889,493 | $4.6M |
| Shareholders' equity | $15.2M | $20.0M | $24.3M | $29.0M | $35.4M | $8.8M | $5.2M | $5.4M | $7.9M | $987,475 |
Growth · year-over-year · Revenue CAGR -5.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | +0.0% | — | — | — | — | -77.5% | +206.9% | +20.8% | -96.8% |
| EPS growth | — | — | -171.1% | — | — | — | — | — | — | — |
| Free cash flow growth | — | — | — | — | — | — | — | — | — | -369.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-10-31. Facts plus Stocktoria's own computed scores — not investment advice.